KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Other Non-Current Assets (2016 - 2025)

Xenon Pharmaceuticals (XENE) has disclosed Other Non-Current Assets for 9 consecutive years, with $7.2 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets fell 4.6% to $7.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $7.2 million, a 4.6% decrease, with the full-year FY2025 number at $7.2 million, down 4.6% from a year prior.
  • Other Non-Current Assets was $7.2 million for Q4 2025 at Xenon Pharmaceuticals, up from $7.1 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $9.2 million in Q2 2025 to a low of $7.1 million in Q3 2025.
  • A 4-year average of $7.7 million and a median of $7.5 million in 2024 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: dropped 8.2% in 2024, then increased 23.89% in 2025.
  • Xenon Pharmaceuticals' Other Non-Current Assets stood at $7.8 million in 2022, then fell by 4.58% to $7.4 million in 2023, then rose by 1.35% to $7.5 million in 2024, then dropped by 4.6% to $7.2 million in 2025.
  • Per Business Quant, the three most recent readings for XENE's Other Non-Current Assets are $7.2 million (Q4 2025), $7.1 million (Q3 2025), and $9.2 million (Q2 2025).